MNKD logo

Mannkind Corporation

MNKD

MNKD: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

more

Show MNKD Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MNKD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MNKD's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jan 19, 2023 Issue: Health Issues
  • $30,000 Oct 18, 2022 Issue: Health Issues
  • $30,000 Jul 20, 2022 Issue: Health Issues
  • $20,000 Apr 20, 2022 Issue: Health Issues
  • $30,000 Jan 20, 2022 Issue: Health Issues
  • $30,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $30,000 Jul 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jun 22, 2021 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
U.S. Patents

New patents grants

  • Patent Title: Time delay mechanism for a hydraulic drug delivery device Aug. 22, 2023
  • Patent Title: Communication accessory for a drug delivery device Aug. 08, 2023
  • Patent Title: Moving basal engine for a fluid delivery device Jun. 06, 2023
  • Patent Title: Fluid delivery device having an insertable prefilled cartridge May. 30, 2023
  • Patent Title: Hydraulically actuated pump for fluid administration May. 09, 2023
  • Patent Title: Dry powder drug delivery system and methods Apr. 11, 2023
  • Patent Title: Diketopiperazine microparticles with defined specific surface areas Mar. 21, 2023
  • Patent Title: Use of ultrarapid acting insulin Jan. 24, 2023
  • Patent Title: Apparatus, system and method for detecting and monitoring inhalations Oct. 25, 2022
  • Patent Title: Methods for the synthesis of activated ethylfumarates and their use as intermediates Oct. 25, 2022
  • Patent Title: Insufflation apparatus and methods Sep. 20, 2022
  • Patent Title: Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine Sep. 13, 2022
  • Patent Title: High capacity diketopiperazine microparticles and methods Sep. 06, 2022
  • Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-n-protected amino ester May. 31, 2022
  • Patent Title: Inhalable dry powder pharmaceutical composition Apr. 19, 2022
  • Patent Title: Catalysis of diketopiperazine synthesis Apr. 05, 2022
  • Patent Title: Dry powder inhaler and system for drug delivery Feb. 08, 2022
  • Patent Title: Microcrystalline diketopiperazine compositions and methods Dec. 07, 2021
  • Patent Title: Dry powder inhaler and system for drug delivery Nov. 30, 2021
  • Patent Title: Composition and method for reducing hypoglycemia events in diabetes treatment Sep. 07, 2021
  • Patent Title: Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces Aug. 31, 2021
  • Patent Title: Reactor for producing pharmaceutical particles in a precipitation process Aug. 31, 2021
  • Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Aug. 03, 2021
  • Patent Title: Use of ultrarapid acting insulin May. 25, 2021
  • Patent Title: Heat-stable dry powder pharmaceutical compositions and methods May. 25, 2021
  • Patent Title: Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents May. 25, 2021
  • Patent Title: Diketopiperazine salts for drug delivery and related methods Feb. 09, 2021
  • Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-n-protected amino ester Dec. 22, 2020
  • Patent Title: Method of treating diabetes type 2 by administering ultrarapid acting insulin Dec. 08, 2020
  • Patent Title: Methods for the synthesis of activated ethylfumarates and their use as intermediates Dec. 08, 2020
  • Patent Title: Diketopiperazine microparticles with defined specific surface areas Sep. 15, 2020
  • Patent Title: Use of ultrarapid acting insulin Sep. 15, 2020
  • Patent Title: Dry powder inhaler and system for drug delivery Aug. 25, 2020
  • Patent Title: Microcrystalline diketopiperazine compositions and methods Aug. 18, 2020
  • Patent Title: Dry powder drug delivery system and methods Aug. 18, 2020
  • Patent Title: Interactive apparatus and method for real-time profiling of inhalation efforts Jun. 09, 2020
  • Patent Title: Formation of n-protected 3,6-bis-(4-aminoalkyl)-2,5,diketopiperazine May. 05, 2020
  • Patent Title: Diketopiperazine salts for drug delivery and related methods Mar. 10, 2020
  • Patent Title: Formation of n-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-n-protected amino ester intermediate Mar. 03, 2020
  • Patent Title: Mouthpiece cover for an inhaler Feb. 18, 2020
  • Patent Title: Apparatus and method for cryogranulating a pharmaceutical composition Dec. 10, 2019
  • Patent Title: Microcrystalline diketopiperazine compositions and methods Sep. 24, 2019
  • Patent Title: Heat-stable dry powder pharmaceutical compositions and methods Sep. 17, 2019
  • Patent Title: Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent Aug. 13, 2019
  • Patent Title: High capacity diketopiperazine microparticles and methods Aug. 13, 2019
  • Patent Title: Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents Jul. 23, 2019
  • Patent Title: Dry powder drug delivery system Jul. 09, 2019
  • Patent Title: Inhaler Jun. 18, 2019
  • Patent Title: Use of ultrarapid acting insulin Jun. 04, 2019
  • Patent Title: Methods and compositions for treating pain Apr. 16, 2019
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of MNKD in WallStreetBets Daily Discussion

MNKD News

Recent insights relating to MNKD

CNBC Recommendations

Recent picks made for MNKD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MNKD

Corporate Flights

Flights by private jets registered to MNKD